Ann-Lii Cheng, MD, discusses a phase III trial of lenvatinib vs sorafenib in the first-line treatment of patients with unresectable hepatocellular carcinoma.
Phase 3 VERIFY Trial Investigates Rusfertide’s Potential in Polycythemia Vera
July 16th 2024In an interview, Aniket Bankar, MD, discussed the background, design, and goals of the phase 3 VERIFY trial of the hepcidin mimetic rusfertide for the treatment of patients with polycythemia vera.
Read More